Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has received an average rating of "Buy" from the nine research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $35.71.

Several research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. JPMorgan Chase & Co. cut their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Finally, Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and lifted their target price for the company from $11.00 to $24.00 in a research report on Thursday, August 1st.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. The trade was a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 51,745 shares of company stock worth $775,867 over the last ninety days. 8.40% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after purchasing an additional 1,002 shares during the period. Quest Partners LLC raised its stake in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after purchasing an additional 7,668 shares during the period. SG Americas Securities LLC bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $113,000. Point72 DIFC Ltd bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $124,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at $163,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock traded up $0.18 during mid-day trading on Thursday, reaching $13.72. The stock had a trading volume of 584,189 shares, compared to its average volume of 956,040. Day One Biopharmaceuticals has a fifty-two week low of $11.30 and a fifty-two week high of $18.07. The stock's 50-day simple moving average is $14.35 and its 200-day simple moving average is $14.18. The firm has a market capitalization of $1.38 billion, a PE ratio of -13.32 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same period last year, the business posted ($0.54) EPS. On average, research analysts forecast that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.